ZIVO Bioscience (ZIVO) Competitors $19.00 +0.17 (+0.89%) (As of 12/20/2024 04:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsTrends ZIVO vs. ITOS, ELDN, URGN, AVIR, CMRX, RZLT, HRTX, MRSN, ATYR, and FULCShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include iTeos Therapeutics (ITOS), Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Atea Pharmaceuticals (AVIR), Chimerix (CMRX), Rezolute (RZLT), Heron Therapeutics (HRTX), Mersana Therapeutics (MRSN), Atyr PHARMA (ATYR), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. iTeos Therapeutics Eledon Pharmaceuticals UroGen Pharma Atea Pharmaceuticals Chimerix Rezolute Heron Therapeutics Mersana Therapeutics Atyr PHARMA Fulcrum Therapeutics iTeos Therapeutics (NASDAQ:ITOS) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Do institutionals & insiders have more ownership in ITOS or ZIVO? 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in ITOS or ZIVO? ZIVO Bioscience received 59 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 78.43% of users gave iTeos Therapeutics an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote. CompanyUnderperformOutperformiTeos TherapeuticsOutperform Votes4078.43% Underperform Votes1121.57% ZIVO BioscienceOutperform Votes9960.74% Underperform Votes6439.26% Which has better valuation & earnings, ITOS or ZIVO? ZIVO Bioscience has lower revenue, but higher earnings than iTeos Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M7.75-$112.64M-$3.15-2.36ZIVO Bioscience$15.85K4,250.73-$7.78M-$4.88-3.89 Is ITOS or ZIVO more profitable? iTeos Therapeutics has a net margin of 0.00% compared to ZIVO Bioscience's net margin of -11,068.75%. ZIVO Bioscience's return on equity of 0.00% beat iTeos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -20.11% -17.50% ZIVO Bioscience -11,068.75%N/A -2,240.92% Does the media refer more to ITOS or ZIVO? In the previous week, iTeos Therapeutics had 5 more articles in the media than ZIVO Bioscience. MarketBeat recorded 6 mentions for iTeos Therapeutics and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.99 beat iTeos Therapeutics' score of -0.07 indicating that ZIVO Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iTeos Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ZIVO Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ITOS or ZIVO? iTeos Therapeutics currently has a consensus target price of $22.25, suggesting a potential upside of 199.87%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe iTeos Therapeutics is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00ZIVO Bioscience 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, ITOS or ZIVO? iTeos Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. SummaryiTeos Therapeutics beats ZIVO Bioscience on 12 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.38M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.93%4.22%P/E Ratio-3.8946.7389.6617.18Price / Sales4,250.73415.011,115.28116.98Price / CashN/A182.1042.8237.86Price / Book-23.463.894.794.78Net Income-$7.78M-$42.21M$120.04M$225.60M7 Day Performance-4.28%-2.15%-1.91%-1.23%1 Month Performance-9.52%4.20%11.48%3.36%1 Year Performance1,339.39%18.39%30.60%16.60% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO BioscienceN/A$19.00+0.9%N/A+1,307.4%$67.38M$15,850.00-3.8910News CoverageGap DownITOSiTeos Therapeutics3.5018 of 5 stars$7.76+1.0%$25.25+225.4%-28.4%$283.50M$35M-2.4490Analyst ForecastELDNEledon Pharmaceuticals2.9252 of 5 stars$4.50+2.7%$16.00+255.6%+196.6%$268.83MN/A-2.3310Positive NewsHigh Trading VolumeURGNUroGen Pharma3.8754 of 5 stars$11.32-0.3%$43.70+286.0%-28.4%$265.45M$82.71M-3.60200AVIRAtea Pharmaceuticals3.0689 of 5 stars$3.12+6.5%$6.88+120.5%+5.6%$263.53M$351.37M-1.5370High Trading VolumeCMRXChimerix4.3425 of 5 stars$2.92-1.0%$8.50+191.1%+218.1%$262.63M$320,000.00-3.1472RZLTRezolute3.1822 of 5 stars$4.52-1.5%$24.13+433.7%+387.8%$261.90MN/A-3.6140Positive NewsHRTXHeron Therapeutics3.9582 of 5 stars$1.69+5.6%$5.67+235.3%-2.5%$257.04M$137.74M-8.89300Analyst DowngradeGap DownMRSNMersana Therapeutics4.3105 of 5 stars$2.08-3.3%$6.00+188.5%-16.2%$256.94M$36.85M-3.52150Positive NewsATYRAtyr PHARMA2.4771 of 5 stars$3.04-0.7%$19.25+533.2%N/A$255.18M$235,000.00-3.2656News CoverageFULCFulcrum Therapeutics1.7135 of 5 stars$4.43+11.9%$9.33+110.7%-22.6%$238.95M$80.87M-13.68100 Related Companies and Tools Related Companies ITOS Alternatives ELDN Alternatives URGN Alternatives AVIR Alternatives CMRX Alternatives RZLT Alternatives HRTX Alternatives MRSN Alternatives ATYR Alternatives FULC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZIVO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
